| D02593 | |
| D number | D02593 |
| Classification | Drug |
| Name | Pantoprazole sodium (USAN); Pantoprazole sodium hydrate (JAN); Protonix (TN) |
| Component | - |
| Formula | (C16H14F2N3O4S. Na)2. 3H2O |
| Exact mass | 864.1458 |
| Mol weight | 864.7491 |
| Structural formula |  |
| Sequence | - |
| Sequence type | - |
| Source | - |
| Upper DGroup | Gastrointestinal agent DG01646 Proton pump inhibitor (PPI) DG01975 Agents for peptic ulcer DG01646 Proton pump inhibitor (PPI) Cyp substrate DG01639 CYP2C19 substrate Cyp inhibitor DG01933 CYP2C19 inhibitor |
| Remark | ATC code: A02BC02 Chemical group: DG00021 Zollinger-Ellison syndrome [DS:H01522] |
| Activity | - |
| Disease | - |
| Comment | Benzimidazole derivative Treatment of various acid-related gastrointestinal diseases, including acute erosive esophagitis healing and maintenance, treatment of hypersecretory conditions, Zollinger-Ellison Syndrome (ZES), and eradication of Helicobacter pylori infection |
| Target | ATP4A [HSA:495] [KO:K01542]; ATP4B [HSA:496] [KO:K01543] |
| Metabolism | Enzyme: CYP2C19 [HSA:1557] |
| Interaction | Genomic biomarker: CYP2C19 [HSA:1557] CYP inhibition: CYP2C19 [HSA:1557] |
| Other DBs | CAS: 164579-32-2 PubChem: 17396764 DrugBank: DB00213 LigandBox: D02593 |
| KCF data | - |